The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Key Points: Combination treatment with RG7112 and Peg-IFNα 2a targets primitive JAK2V617F+ progenitor cells in myeloproliferative neoplasms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · cited 1×
“The cis-imidazoline compounds termed nutlins were the first potent and selective MDM2 inhibitors, and their discovery stimulated widespread interest in the design of small molecule p53-MDM2 inhibitors.(22,25) We reported that combination treatment with low doses of Peg IFNa 2a and nutlin-3, an antagonist of”
Background
Cited by
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Myeloproliferative neoplasm stem cells
Mead, A. J., & Mullally, A. (2017) · Blood · doi:10.1182/blood-2016-10-696005 · Cited by 169
Oral idasanutlin in patients with polycythemia vera
Mascarenhas, J., Lu, M., Kosiorek, H., Virtgaym, E., Xia, L., Sandy, L., Mesa, R., Petersen, B., Farnoud, N., Najfeld, V., et al. (2019) · Blood · doi:10.1182/blood.2018893545 · Cited by 87
Self-citationMDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
“RG7112 results in p53 accumulation and activation of p53 signaling in cancer cells that express wild-type p53, which has been shown to deplete MDM2-upregulated progenitor/stem cells and inhibit the growth of human tumor xenografts by causing cell cycle arrest and apoptosis [62,63].”
Background
Metadata
- Authors
- Lu, M., Xia, L., Li, Y., Wang, X., & Hoffman, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-07-31
- Volume
- 124
- Issue
- 5
- Pages
- 771-779
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2131752437
- Cited by
- 68
- References
- 1
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. https://app.cochat.ai/papers/10.1182/blood-2013-11-536854
- The paper
- Lu, M., Xia, L., Li, Y., Wang, X., & Hoffman, R. (2014). The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood. https://doi.org/10.1182/blood-2013-11-536854
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.